Yahoo
TSXV - Delayed Quote CAD

Medicure Inc. (MPH.V)

4.2300 -0.0700 (-1.63%)
At close: November 2 at 3:59:24 PM EST
Chart Range Bar
Loading chart for MPH.V
  • Previous Close 4.3000
  • Open 4.3000
  • Bid 4.0200 x --
  • Ask 4.2800 x --
  • Day's Range 4.0300 - 4.4700
  • 52 Week Range 0.8500 - 4.9500
  • Volume 34,102
  • Avg. Volume 4,633
  • Market Cap (intraday) 44.146M
  • Beta (5Y Monthly) 1.21
  • PE Ratio (TTM) --
  • EPS (TTM) -0.7100
  • Earnings Date (est.) Nov 19, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order, and online pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.

www.medicure.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

MPH.V
238.40%
S&P/TSX Composite index (^GSPTSE)
12.35%

1-Year Return

MPH.V
264.66%
S&P/TSX Composite index (^GSPTSE)
18.31%

3-Year Return

MPH.V
153.29%
S&P/TSX Composite index (^GSPTSE)
82.41%

5-Year Return

MPH.V
345.26%
S&P/TSX Composite index (^GSPTSE)
69.11%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY20
Revenue 2.68M
Earnings 19k
Profit Margin 0.71%

Q3

FY19

Q4

FY19

Q1

FY20

Q2

FY20

-15M
-10M
-5M
0
5M
-400.0%
-300.0%
-200.0%
-100.0%
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -23.23%

  • Return on Assets (ttm)

    -17.78%

  • Return on Equity (ttm)

    -49.88%

  • Revenue (ttm)

    32.08M

  • Net Income Avi to Common (ttm)

    -7.45M

  • Diluted EPS (ttm)

    -0.7100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.83M

  • Total Debt/Equity (mrq)

    6.01%

  • Levered Free Cash Flow (ttm)

    204.38k

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: